Subscribe
17 October 2024NewsAmericasMarisa Woutersen

LSPN Fall: Why Big Pharma is facing 'a balancing act'

As  the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies. Marisa Woutersen reports.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
GSK fires pair of COVID and RSV lawsuits at Moderna
16 October 2024   UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.
Europe
Roche to outside counsel: ‘Law firms must adapt to the modern world’
9 October 2024   Roche’s chief trademark officer has more than filing and searches on his to-do list—and external counsel must keep up, he tells Marisa Woutersen.


Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024

Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024

More on this story

Americas
GSK fires pair of COVID and RSV lawsuits at Moderna
16 October 2024   UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.
Europe
Roche to outside counsel: ‘Law firms must adapt to the modern world’
9 October 2024   Roche’s chief trademark officer has more than filing and searches on his to-do list—and external counsel must keep up, he tells Marisa Woutersen.

More on this story

Americas
GSK fires pair of COVID and RSV lawsuits at Moderna
16 October 2024   UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.
Europe
Roche to outside counsel: ‘Law firms must adapt to the modern world’
9 October 2024   Roche’s chief trademark officer has more than filing and searches on his to-do list—and external counsel must keep up, he tells Marisa Woutersen.

More features

PierFerd adds AI patent partner with ‘dynamic experience’
GSK fires pair of COVID and RSV lawsuits at Moderna
How post-filing data rescued Novo Nordisk’s Ozempic patent in China
Novo Nordisk targets Canada’s largest generics maker over diabetes drug
Jones Day hires pharma and high-tech patent litigator to London office
Powell Gilbert co-founder moves to US firm
GSK: ‘Whoever moves first has UPC advantage’
Pfizer and BioNTech win UK COVID-19 dispute